Mereo BioPharma Group plc (Mereo) (MREO) News

Mereo BioPharma Group plc (Mereo) (MREO): $1.39

0.27 (+24.11%)

POWR Rating

Component Grades













Add MREO to Watchlist
Sign Up

Industry: Biotech


of 399

in industry

Filter MREO News Items

MREO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest MREO News From Around the Web

Below are the latest news stories about Mereo Biopharma Group plc that investors may wish to consider to help them evaluate MREO as an investment opportunity.

Do Hedge Funds Love Mereo BioPharma Group plc (MREO)?

In this article you are going to find out whether hedge funds think Mereo BioPharma Group plc (NASDAQ:MREO) is a good investment right now.

Insider Monkey | January 12, 2022

UAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial

A UAB investigated covid treatment from Mereo BioPharma Group shows positive results in early clinical trial.

Yahoo | December 29, 2021

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Mereo Biopharma Group Plc (MREO)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and Mereo Biopharma Group Plc (MREO – Research Report) with bullish sentiments. Merck & Company (MRK) In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company, with a price target of $100.00. The company's shares closed last Wednesday at $76.05. According to TipRanks.

Howard Kim on TipRanks | December 22, 2021

Investors Take Advantage Of -3.03% Loss In Mereo BioPharma Group plc (NASDAQ: MREO)

Mereo BioPharma Group plc (NASDAQ:MREO) traded at $1.60 at last check on Wednesday, December 22, made a downward move of -3.03% on its previous days price. Looking at the stock we see that its previous close was $1.65 and the beta (5Y monthly) reads 1.49 with the days price range being $1.62 $1.70. In Investors Take Advantage Of -3.03% Loss In Mereo BioPharma Group plc (NASDAQ: MREO) Read More »

Stocks Register | December 22, 2021

UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease

Alvelestat reported safe and well-tolerated in patients with COVID-19 Alvelestat, on top of standard of care resulted in a more rapid time to improvement in WHO Disease Severity score of >=2 in the first 5-7 days compared to placebo plus standard of care LONDON and REDWOOD CITY, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat,

Yahoo | December 22, 2021

Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ...

Investment company Rubric Capital Management LP (Current Portfolio) buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, Amryt Pharma PLC, Radius Health Inc, sells Kraton Corp, , Tronox Holdings PLC, TTM Technologies Inc, Popular Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Rubric Capital Management LP.

Yahoo | December 17, 2021

Needham Thinks Mereo Biopharma Group Plc’s Stock is Going to Recover

> Based on Mereo Biopharma Group Plc's latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $0. In comparison, last year the company had a net profit of $0. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases.

Austin Angelo on TipRanks | December 13, 2021

Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting

LONDON and REDWOOD CITY, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced the presentation of data from the initial seven patients in an investigator-sponsored study of alvelestat in patients with BOS following hematopoietic stem cell transplantation (“HCT”). These data were presented at the 63rd American Society of Hematology (ASH) Annua

Yahoo | December 13, 2021

Mereo BioPharma: Anti-TIGIT Developer In Mid-Stage Development

No summary available.

Seeking Alpha | December 8, 2021

Could Mereo BioPharma Group plc (NASDAQ: MREO) Post Life-Changing Returns?

In the last trading session, 1.33 million Mereo BioPharma Group plc (NASDAQ:MREO) shares changed hands as the companys beta touched 0. With the companys per share price at $1.60 changed hands at -$0.07 or -4.19% during last session, the market valuation stood at $180.80M. MREOs last price was a discount, traded about -194.38% off its Could Mereo BioPharma Group plc (NASDAQ: MREO) Post Life-Changing Returns? Read More »

Marketing Sentinel | December 6, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4862 seconds.